Literature DB >> 11685704

Renal anomalies in the VATER animal model.

J Merei1, A Batiha, I B Hani, M El-Qudah.   

Abstract

BACKGROUND
PURPOSE: Renal anomalies are a prominent feature of the VATER association. Administration of Adriamycin to timed-pregnant rats resulted in a spectrum of anomalies similar to the human VATER association. The aim of this study is to describe the renal anomalies in the Adriamycin animal model.
METHODS: Timed-pregnant Sprague-Dawley rats were injected with Adriamycin intraperitoneally at a dose of 2 mg/kg on days 6 through 9 of gestation. Full-term fetuses were fixed in Bouin's solution and serial transverse sections were analyzed by light microscopy. All specimens were compared with suitable controls.
RESULTS: In experimental animals, renal anomalies were found in 98% of the examined fetuses. Bilateral hydroureteronephrosis with kinking of the ureters was obvious. Ureteric atresia led to obstructive uropathy. Bladder agenesis occurred in all experimental animals. Mesonephric ducts were seen joining a proximally blind-ending urethra in male animals. In females both paramesonephric ducts ended blindly after joining each other, and this resulted in vaginal atresia. In association with imperforate anus, a recto-urethral and a recto-urogenital fistula was seen in male and female fetuses, respectively.
CONCLUSIONS: Bladder agenesis was an important feature in the Adriamycin animal model. Bilateral hydronephrosis resulted from blind-ending ureters. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685704     DOI: 10.1053/jpsu.2001.27962

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Esophageal atresia and other visceral anomalies in a modified Adriamycin rat model and their correlations with amniotic fluid volume variations.

Authors:  Willy M G França; Anderson Gonçalves; Suzana G Moraes; Luis A V Pereira; Lourenço Sbragia
Journal:  Pediatr Surg Int       Date:  2004-08-26       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.